Healthcare Testing Services Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Service Type (Chemical Testing, Microbiological Testing, Toxicology Testing, Stability Testing, Others), By Product Type (Anti-viral Drugs, HIV Drugs, Fertility Drugs, Anti-diabetic Drugs, Respiratory Drugs, Anticoagulants, Medical Devices, Pharmaceutical Packaging, Others), By Development Stage (Preclinical, Clinical, Manufacturing), By End User (Pharmaceutical Industry, Contract Research Organization, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.46 Billion
CAGR (2026-2031)	5.71%
Fastest Growing Segment	Chemical Testing
Largest Market	North America
Market Size (2031)	USD 9.01 Billion

Market Overview

The Global Healthcare Testing Services Market will grow from USD 6.46 Billion in 2025 to USD 9.01 Billion by 2031 at a 5.71% CAGR. Global Healthcare Testing Services encompass analytical and bioanalytical testing solutions utilized by pharmaceutical and medical device companies to ensure product safety, quality, and regulatory compliance throughout the development and manufacturing lifecycles. The market is primarily driven by the increasing complexity of drug molecules, such as biologics, and the strategic shift toward outsourcing to mitigate operational costs. Additionally, heightened regulatory scrutiny acts as a pivotal growth factor, compelling manufacturers to adhere to rigorous quality standards. According to the U.S. Food and Drug Administration's FY2024 Report on the State of Pharmaceutical Quality, the agency conducted 989 drug quality assurance inspections in fiscal year 2024, a 27% increase from the previous year.

However, the market encounters a substantial challenge regarding the scarcity of skilled professionals required to manage complex testing methodologies. The limited pool of qualified analysts capable of operating advanced instrumentation and interpreting intricate data sets creates operational bottlenecks and increases labor costs for service providers. This talent gap, exacerbated by the substantial capital investment needed to maintain accredited laboratories, restricts the scalability of operations and could significantly impede the broader expansion of the global healthcare testing sector.

Key Market Drivers

Surging Global Prevalence of Chronic and Infectious Diseases serves as a primary catalyst propelling the Global Healthcare Testing Services Market. As the incidence of complex conditions such as tuberculosis, cancer, and diabetes intensifies worldwide, pharmaceutical companies and public health organizations are ramping up demand for comprehensive diagnostic testing and bioanalytical support to accelerate treatment development. This trend is particularly acute for infectious diseases, where rapid detection and surveillance testing are critical for managing outbreaks and ensuring patient safety. According to the World Health Organization, October 2024, in the 'Global Tuberculosis Report 2024', approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, the highest number recorded since global monitoring began in 1995. This escalating disease burden directly correlates with increased volumes of clinical trial testing and post-market surveillance studies required to validate new therapeutic interventions.

Simultaneously, the Expansion of Biologics and Biosimilars R&D Pipelines is fundamentally reshaping the testing services landscape. Unlike traditional small-molecule drugs, large-molecule therapies such as monoclonal antibodies and cell therapies require highly specialized, sensitive, and expensive analytical testing methodologies to characterize their potency, purity, and immunogenicity. This shift forces manufacturers to outsource these intricate functions to accredited laboratories equipped with advanced instrumentation. According to the Drug, Chemical & Associated Technologies Association, July 2024, in the 'Innovation Scorecard', the U.S. FDA approved 17 new therapeutic biologics in 2023, which represented 31% of all new drug approvals, highlighting the industry's decisive pivot toward complex molecules. The financial magnitude of this sector is evident in the performance of leading service providers; according to Eurofins Scientific, February 2024, in the '2023 Full Year Results', the company reported total revenues of €6,515 million, reflecting the sustained industrial demand for outsourced analytical testing operations.

Download Free Sample Report

Key Market Challenges

The scarcity of skilled professionals constitutes a primary obstacle hampering the growth of the Global Healthcare Testing Services Market. As pharmaceutical and medical device companies require increasingly complex analytical and bioanalytical testing, the industry faces a critical shortage of qualified analysts capable of managing these advanced methodologies. This talent gap leads to operational inefficiencies, including extended turnaround times and reduced sample processing capacity. Service providers are consequently forced to limit their client intake and delay project timelines, which directly restricts revenue generation and market expansion efforts.

Furthermore, the high cost of recruiting and retaining specialized staff exacerbates the financial burden on testing facilities. This workforce constraint is substantiated by recent industry data. According to the American Society for Clinical Pathology, in its 2024 Vacancy Survey, anatomic pathology departments recorded a vacancy rate of 28.5 percent, underscoring the severity of the labor shortage in critical testing areas. Such high vacancy rates prevent laboratories from fully utilizing their advanced instrumentation and infrastructure. Without a sufficient workforce to support scaling operations, testing service providers remain unable to meet the rising global demand, thereby stalling the broader development of the healthcare testing sector.

Key Market Trends

The Integration of Artificial Intelligence for Enhanced Diagnostic Precision is revolutionizing laboratory workflows by automating complex image analysis and improving clinical decision-making. Laboratories are increasingly deploying machine learning algorithms to process vast datasets in pathology and radiology, thereby reducing human error and identifying subtle biomarkers that traditional methods might miss. This technological shift is accelerating the commercial availability of smart diagnostic tools and facilitating faster regulatory clearances for software-based medical solutions. According to MedTech Dive, October 2024, in the article 'The number of AI medical devices has spiked in the past decade', the U.S. Food and Drug Administration authorized 221 AI or machine learning-enabled medical devices in 2023, marking a significant increase in the validation of these technologies for clinical use.

Concurrently, the Surge in Genomic and Precision Medicine Testing Services is shifting the diagnostic paradigm from generalized screening to personalized patient profiling. Unlike standard bioanalytical testing utilized for drug substance characterization, this trend focuses on identifying hereditary risks and guiding targeted therapies for individual patients, particularly in oncology and prenatal care. Service providers are responding by expanding their portfolios to include advanced molecular diagnostics that offer deeper clinical insights and facilitate individualized treatment plans. This robust demand is evident in recent industrial performance; according to Quest Diagnostics, February 2024, in the 'Fourth Quarter and Full Year 2023 Financial Results', the company delivered double-digit revenue growth in its advanced clinical areas, specifically prenatal and hereditary genetics, underscoring the market adoption of specialized precision testing.

Segmental Insights

The Chemical Testing segment is currently positioning itself as the fastest-growing category within the Global Healthcare Testing Services Market, driven primarily by heightened regulatory scrutiny regarding pharmaceutical product safety. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have enforced stringent guidelines for comprehensive impurity profiling, particularly regarding nitrosamines and elemental contaminants in active ingredients. This escalation in compliance standards compels pharmaceutical manufacturers to increasingly outsource rigorous analytical evaluations to specialized laboratories. Consequently, the critical demand for precise chemical verification to ensure market authorization is fueling the segment’s rapid expansion.

Regional Insights

North America maintains a leading position in the global healthcare testing services market, driven by extensive healthcare infrastructure and substantial healthcare expenditure. The region benefits from a high concentration of key industry players and increased demand for diagnostic screening due to the prevalence of chronic diseases. Additionally, the regulatory framework enforced by the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) ensures rigorous standards for laboratory operations. This alignment of strong market demand and established regulatory oversight supports the sustained expansion of regional testing services.

Recent Developments

• In September 2025, Labcorp announced a strategic collaboration with Roche to enhance its digital pathology capabilities by implementing FDA-cleared slide scanners across its network. This partnership aims to enable pathologists to diagnose patients using digital images, thereby streamlining workflows and supporting the future integration of artificial intelligence into diagnostic processes. The initiative combines the company's extensive diagnostic services with advanced digital pathology solutions to improve the efficiency and timeliness of patient care. The collaboration underscores a commitment to adopting innovative technologies that facilitate faster decision-making and centralized review in clinical trials and routine diagnostics.
• In March 2025, Quest Diagnostics entered into a collaboration with Google Cloud to leverage generative artificial intelligence and data analytics for improving diagnostic information services. This partnership focuses on streamlining data management and personalizing the experience for patients, healthcare providers, and employees by utilizing cloud-based technologies. The company intends to use these advanced capabilities to analyze vast amounts of laboratory data, aiming to generate novel insights and automate complex administrative tasks. The initiative represents a significant step in using digital innovation to enhance the quality and accessibility of healthcare testing services.
• In October 2024, Thermo Fisher Scientific launched a new integrated service offering known as Accelerator Drug Development to speed up the molecule-to-medicine journey for biotechnology and pharmaceutical customers. This solution combines contract development and manufacturing capabilities with clinical research services to provide a seamless pathway from early-stage testing to commercial manufacturing. By connecting these critical steps, the company aims to simplify complex drug development processes, mitigate risks, and improve the efficiency of bringing new therapies to patients. The launch highlights the company's strategy to support customers in tackling global health challenges through comprehensive, end-to-end service solutions.
• In June 2024, Charles River Laboratories announced the opening of a new Accelerator and Development Lab (CRADL) facility in Somerville, Massachusetts, to support the growing needs of the local biopharmaceutical industry. The new facility provides flexible, turnkey vivarium and bench space, allowing researchers and early-stage companies to launch or expand their drug research programs without the need for building their own infrastructure. Located in a key life sciences hub, the site offers on-demand in vivo study support and access to the company’s broader portfolio of integrated drug discovery and non-clinical development resources. This expansion aims to facilitate collaboration and accelerate the development of new therapeutics.

Key Market Players

• Eurofins Scientific (Ireland) Limited
• Thermo Fisher Scientific Inc.
• Microbac Laboratories, Inc.
• ARL Bio Pharma, Inc.
• EM Topco Limited
• Intertek Group plc
• Moderna, Inc.
• ZYUS Life Sciences Corp
• Alcami Corporation
• F. Hoffmann-La Roche Ltd

By Service Type	By Product Type	By Development Stage	By End User	By Region
Chemical Testing Microbiological Testing Toxicology Testing Stability Testing Others	Anti-viral Drugs HIV Drugs Fertility Drugs Anti-diabetic Drugs Respiratory Drugs Anticoagulants Medical Devices Pharmaceutical Packaging Others	Preclinical Clinical Manufacturing	Pharmaceutical Industry Contract Research Organization Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Healthcare Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Healthcare Testing Services Market, By Service Type:

• Chemical Testing
• Microbiological Testing
• Toxicology Testing
• Stability Testing
• Others

• Healthcare Testing Services Market, By Product Type:

• Anti-viral Drugs
• HIV Drugs
• Fertility Drugs
• Anti-diabetic Drugs
• Respiratory Drugs
• Anticoagulants
• Medical Devices
• Pharmaceutical Packaging
• Others

• Healthcare Testing Services Market, By Development Stage:

• Preclinical
• Clinical
• Manufacturing

• Healthcare Testing Services Market, By End User:

• Pharmaceutical Industry
• Contract Research Organization
• Others

• Healthcare Testing Services Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE